Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children
复制标题
DOI：
10.3324/haematol.11239
复制
发表时间：
2007-10-31
期刊：
影响因子：
10.1
通讯作者：
Mann, Georg
中科院分区：
文献类型：
--
作者：
Kager, Leo;Lion, Thomas;Mann, Georg
从对患有TCF3-Pbx1的儿童的分析中得出的经验教训都可以帮助确定对这种白血病亚型至关重要的治疗成分。在奥地利的ALL-BFM试验中接受治疗的859名ALL儿童中，31名(3.6%)患有TCF3-PBX1 ALL。这31例患者的5年无事件存活率为90%+/-5%。所有在ALL-BFM 86试验中接受治疗的TCF3-Pbx1患者的预后比在后来的试验中接受所有TCF3-Pbx1治疗的患者更差。这些数据证明，当代ALL-BFM治疗对患有TCF3-PBX1 ALL的儿童非常有效。早期实施剂量强化缓解诱导可能是治疗的重要组成部分。
Lessons from the analysis of children with TCF3-PBX1 ALL could help to identify treatment components essential for this leukemia subtype. Of 859 children with ALL who were treated in ALL-BFM trials in Austria, 31 (3.6%) had a TCF3-PBX1 ALL. The 5-year event-free survival rate for these 31 patients was 90%+/- 5%. Patients with TCF3-PBX1 ALL treated on the ALL-BFM 86 trial had a poorer outcome than patients with TCF3-PBX1 ALL treated on later trials. These data document that contemporary ALL-BFM treatment is highly effective in children with TCF3-PBX1 ALL. Implementation of early dose-intensified remission induction may be an essential treatment component.